Cargando…
BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α(2B) Antagonist
[Image: see text] After acute myocardial infarction, early reperfusion is the most effective strategy for reducing cardiac damage and improving clinical outcome. However, restoring blood flow to the ischemic myocardium can paradoxically induce injury by itself (reperfusion injury), with microvascula...
Autores principales: | Meibom, Daniel, Meyer, Jutta, von Buehler, Clemens-Jeremias, Collins, Karl D., Maassen, Stefanie, Gericke, Kersten Matthias, Hüser, Jörg, Mittendorf, Joachim, Ortega Hernandez, Nuria, Schamberger, Jens, Stampfuss, Jan, Straub, Alexander, Torge, Afra, Witowski, Norbert, Wunder, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108358/ https://www.ncbi.nlm.nih.gov/pubmed/36932954 http://dx.doi.org/10.1021/acs.jmedchem.2c01690 |
Ejemplares similares
-
BAY-7081: A
Potent, Selective, and Orally Bioavailable
Cyanopyridone-Based PDE9A Inhibitor
por: Meibom, Daniel, et al.
Publicado: (2022) -
Design and
Preclinical Characterization Program toward
Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention
and Treatment of Thromboembolic Disorders
por: Roehrig, Susanne, et al.
Publicado: (2023) -
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009) -
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
por: Connor, Kathryn M, et al.
Publicado: (2017) -
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases
por: von Nussbaum, Franz, et al.
Publicado: (2015)